AbbVie’s SKYRIZI has been approved by the European Commission for children and adolescents aged 6 and older with moderate to severe plaque psoriasis, extending its use beyond adults. The regulatory expansion is a positive commercial milestone for the product and broadens its addressable market in Europe. The announcement is supportive for AbbVie, though the immediate stock impact is likely limited.
AbbVie’s SKYRIZI has been approved by the European Commission for children and adolescents aged 6 and older with moderate to severe plaque psoriasis, extending its use beyond adults. The regulatory expansion is a positive commercial milestone for the product and broadens its addressable market in Europe. The announcement is supportive for AbbVie, though the immediate stock impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
